Diabetes Pharmacist : Diabetes Pharmacist Blog : Focus Express Mail Pharmacy : Insulin Pumps, Diabetes Supplies and Information

A newly approved diabetes drug, Onglyza, is now available in U.S. pharmacies, effective Friday August 14, 2009.

Bristol Myers-Squibb and AstraZeneca PLC, which co-developed and will co-market the drug, said that Onglyza was approved as an adjunct to diet and exercise to improve blood-sugar control in adults for the treatment of type 2 diabetes mellitus.

It belongs to a class of drugs known as DPP-4 inhibitors, and will compete directly with the only other such drug on the market, Merck & Co.'s (MRK) Januvia, which has had the DPP-4 market to itself since it was introduced in 2006.

For more information on Onglyza go to http://www.onglyza.com/

Click here to learn more about diabetes medications available through Focus Express Mail Pharmacy!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Using noninvasive imaging (Magnetic Resonance Imaging  (MRI) ) for the first time in diabetes research, physicians at Massachusetts General Hospital and Harvard Medical School have discovered how it may aid in the early diagnosis, staging, and treatment of diabetes.

"With noninvasive MRI we have the ability to evaluate beta cell mass, a major factor of insulin secretion that is significantly reduced in type two diabetes and almost gone in type one,” said Anna Moore, MD, lead author of the study. “Knowing the number of functional beta cells left would allow physicians to develop the most appropriate treatment plans for their patients. It would also allow them to respond, change or manipulate those treatment plans at any time,” she said.

• Email This
• Print
• Comments
• Trackbacks
• Share Link